Kyxata Carboplatin 10 mg Intravenous Chemotherapy Multiple-Dose Vial 8 mL (RX0

Kyxata (Carboplatin) 10 mg/mL Injection Kyxata is a brand of carboplatin injection, a platinum-based chemotherapy drug. It comes as a sterile pale-yellow solution where each milliliter (mL) contains 10 mg of carboplatin. (Vial strengths include 20 mg/2 mL, 80 mg/8 mL, and 500 mg/50 mL, all at 10 mg/mL.) Carboplatin works by binding DNA and forming cross-links, blocking DNA replication and causing cancer cell death. Uses (Indications) Advanced ovarian cancer (first-line): Kyxata is used with other chemotherapy agents (e.g. cyclophosphamide) as initial treatment for advanced ovarian carcinoma in adults. Recurrent ovarian cancer: It is also indicated as a single agent for ovarian carcinoma that has recurred after prior chemotherapy. Dosage and Administration Administration: Given only by intravenous infusion (usually by an oncologist or in a cancer clinic). It is not a self-administered drug. Dose calculation: Dosing is based on body size and kidney function. Doctors often use the Calvert formula: Dose (mg) = Target AUC (area under curve) × (GFR + 25), where GFR (glomerular filtration rate) is estimated from creatinine clearance. This ensures the dose is adjusted for each patient’s renal function. Typical dosing: For example, an initial regimen might be 300 mg/m² (or targeting an AUC of 4–6 mg·min/mL) on Day 1, combined with cyclophosphamide, every 4 weeks (for up to 6 cycles). For recurrent disease as a single agent, around 360 mg/m² (or AUC 4–6) on Day 1 every 4 weeks is common. Exact doses will be determined by the treating oncologist. Monitoring: Complete blood counts are checked before each cycle because carboplatin can severely lower blood cell levels. Anti-nausea medications are usually given before the infusion to prevent vomiting. Side Effects and Precautions Kyxata has serious potential side effects, as with most chemotherapy agents. Key points include: Myelosuppression (low blood counts): The most important toxicity is bone marrow suppression. This drug commonly causes neutropenia (low white cells), thrombocytopenia (low platelets), and anemia. This can lead to severe infections, bleeding, or fatigue. Doctors monitor blood counts closely and may delay or reduce doses if counts are too low. Nausea and vomiting: These are common. Patients are typically given antiemetics (anti-vomiting drugs) before and after treatment. Allergic reactions: Kyxata can cause severe hypersensitivity, including anaphylactic reactions, sometimes within minutes of starting the infusion. Medical staff will watch for any rash, difficulty breathing, or other allergic signs during administration. If a serious reaction occurs, the infusion is stopped immediately and managed appropriately. Peripheral neuropathy: Tingling, numbness, or weakness in the hands or feet can occur. Dose adjustments may be needed if neuropathy develops. Other common effects: Hair loss (alopecia) and fatigue are very common. Other frequent side effects include nausea, anemia, low platelet count, and low magnesium or sodium levels. Pregnancy and fertility: Carboplatin can cause fetal harm. Women of childbearing potential must use effective contraception and avoid pregnancy during treatment. Men should also use contraception. Breastfeeding is not recommended. Drug interactions: Avoid concurrent use of certain drugs, especially aminoglycoside antibiotics (e.g. gentamicin). Using these together with carboplatin can increase the risk of kidney damage or hearing loss. Your doctor or pharmacist will check all medications to prevent harmful interactions. Important Information Medical super­vision required: Kyxata is a prescription medication administered only under a doctor’s care. Do not attempt to use it on your own. Monitoring: Frequent lab tests (blood counts, kidney function, electrolytes) are needed before and during treatment. The doctor will adjust dosing or delay cycles based on these results. Consult professionals: This summary is for general information. Individual dosing and safety measures depend on a patient’s health status and should be managed by oncologists or pharmacists. For full prescribing details, healthcare providers can refer to official sources (e.g. FDA’s DailyMed listing for Kyxata). Disclaimer: This information is not medical advice. For personal medical concerns or before starting any medication, please consult a licensed healthcare professional.